(Q28252845)

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

31 March 2020

1 reference

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

31 March 2020

1 reference

Antibody-based therapy for solid tumors

31 March 2020

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

31 March 2020

1 reference

A quantitative analysis of kinase inhibitor selectivity

31 March 2020

1 reference

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

31 March 2020

1 reference

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

A census of human cancer genes

31 March 2020

1 reference

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

31 March 2020

1 reference

Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells

31 March 2020

1 reference

Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers

31 March 2020

1 reference

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

31 March 2020

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

31 March 2020

1 reference

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

31 March 2020

1 reference

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

31 March 2020

1 reference

Showering c-MET-dependent cancers with drugs

31 March 2020

1 reference

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

31 March 2020

1 reference

Drug-sensitive FGFR2 mutations in endometrial carcinoma

31 March 2020

1 reference

Activating mutations in ALK provide a therapeutic target in neuroblastoma

31 March 2020

1 reference

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

31 March 2020

1 reference

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

31 March 2020

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

31 March 2020

1 reference

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

31 March 2020

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

Oncogenic mutations of ALK kinase in neuroblastoma

31 March 2020

1 reference

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

Targeting the RAF-MEK-ERK pathway in cancer therapy

31 March 2020

1 reference

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

31 March 2020

1 reference

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

31 March 2020

1 reference

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation

31 March 2020

1 reference

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

31 March 2020

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

31 March 2020

1 reference

Genetic predictors of MEK dependence in non-small cell lung cancer

31 March 2020

1 reference

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway

31 March 2020

1 reference

EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

31 March 2020

1 reference

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

31 March 2020

1 reference

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors

31 March 2020

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

Modeling genomic diversity and tumor dependency in malignant melanoma

31 March 2020

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

31 March 2020

1 reference

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

31 March 2020

1 reference

Human cancer, PTEN and the PI-3 kinase pathway

31 March 2020

1 reference

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

31 March 2020

1 reference

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

31 March 2020

1 reference

Effects of smoking on the pharmacokinetics of erlotinib

31 March 2020

1 reference

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

31 March 2020

1 reference

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

31 March 2020

1 reference

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

31 March 2020

1 reference

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

31 March 2020

1 reference

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

31 March 2020

1 reference

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

31 March 2020

1 reference

EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

31 March 2020

1 reference

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

31 March 2020

1 reference

Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.

31 March 2020

1 reference

Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high‐grade soft tissue sarcoma

31 March 2020

1 reference

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer

31 March 2020

1 reference

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

31 March 2020

1 reference

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).

31 March 2020

1 reference

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors

31 March 2020

1 reference

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells

31 March 2020

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

31 March 2020

1 reference

Renal effects of anti-angiogenesis therapy: update for the internist

31 March 2020

1 reference

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

31 March 2020

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

31 March 2020

1 reference

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

31 March 2020

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

31 March 2020

1 reference

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

31 March 2020

1 reference

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy

31 March 2020

1 reference

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

31 March 2020

1 reference

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

31 March 2020

1 reference

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

31 March 2020

1 reference

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

31 March 2020

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

31 March 2020

1 reference

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

31 March 2020

1 reference

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

31 March 2020

1 reference

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models

31 March 2020

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

31 March 2020

1 reference

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

31 March 2020

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

31 March 2020

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

31 March 2020

1 reference

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

31 March 2020

1 reference

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

31 March 2020

1 reference

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

31 March 2020

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

High-throughput oncogene mutation profiling in human cancer

31 March 2020

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

31 March 2020

1 reference

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

31 March 2020

1 reference

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

31 March 2020

1 reference

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

31 March 2020

1 reference

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

31 March 2020

1 reference

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

31 March 2020

1 reference

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

31 March 2020

1 reference

FLT3 kinase inhibitors in the management of acute myeloid leukemia.

31 March 2020

1 reference

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

31 March 2020

1 reference

The role of Src in prostate cancer

31 March 2020

1 reference

c-Src and cooperating partners in human cancer

31 March 2020

1 reference

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

31 March 2020

1 reference

Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer

31 March 2020

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

31 March 2020

1 reference

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

31 March 2020

1 reference

KIT gene mutations and copy number in melanoma subtypes

31 March 2020

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

31 March 2020

1 reference

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

31 March 2020

1 reference

Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer

31 March 2020

1 reference

12 December 2020

PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

1 reference

12 December 2020

Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies

1 reference

12 December 2020

Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia

1 reference

12 December 2020

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

1 reference

12 December 2020

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target

1 reference

12 December 2020

Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells

1 reference

12 December 2020

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

12 December 2020